Cardiol Therapeutics Inc. Class A Common Shares (CRDL) Stock Price

CRDLStock

$1.10+8.22%52W

Market Cap$133.66M

P/E—

PEG Ratio—

Div yield—

Beta2.67

CRDL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-26.31%

Price vs S&P 500 (4W)-38.14%

VGM Score62.04

Book Value / Share (Quarterly)$0.15

P/TBV (Annual)6.12x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.15

Price vs S&P 500 (YTD)8.68%

EPS (TTM)$-0.24

10-Day Avg Trading Volume0.30M

EPS Excl Extra (TTM)$-0.24

EPS (Annual)$-0.36

ROI (Annual)-147.38%

Net Profit Margin (5Y Avg)-143204.20%

Cash / Share (Quarterly)$0.16

ROA (Last FY)-115.11%

EBITD / Share (TTM)$-0.25

ROE (5Y Avg)-100.84%

Cash Flow / Share (Annual)$-0.17

P/B Ratio8.03x

P/B Ratio (Quarterly)7.15x

Net Income / Employee (Annual)$-1,441,865

Net Interest Coverage (TTM)-0.89x

ROA (TTM)-140.05%

EPS Incl Extra (Annual)$-0.36

Current Ratio (Annual)4.16x

Quick Ratio (Quarterly)5.01x

3-Month Avg Trading Volume0.19M

52-Week Price Return8.22%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.21

P/S Ratio (Annual)2413.21x

Asset Turnover (Annual)0.00x

52-Week High$2.29

Operating Margin (5Y Avg)-156141.00%

EPS Excl Extra (Annual)$-0.36

CapEx CAGR (5Y)-9.35%

Tangible BV CAGR (5Y)11.86%

26-Week Price Return-16.40%

Quick Ratio (Annual)3.83x

13-Week Price Return0.00%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)5.55x

Enterprise Value$118.23M

Book Value / Share Growth (5Y)-15.08%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-39550.00%

Cash / Share (Annual)$0.15

3-Month Return Std Dev73.83%

Net Income / Employee (TTM)$-1,339,683

ROE (Last FY)-148.32%

Net Interest Coverage (Annual)-9.71x

EPS Basic Excl Extra (Annual)$-0.36

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.24

Receivables Turnover (Annual)0.00x

ROI (TTM)-178.99%

Pretax Margin (5Y Avg)-143204.20%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.21

Price vs S&P 500 (52W)-7.31%

Year-to-Date Return20.61%

5-Day Price Return-11.24%

EPS Normalized (Annual)$-0.36

ROA (5Y Avg)-81.50%

Net Profit Margin (Annual)-39550.00%

Month-to-Date Return-33.33%

Cash Flow / Share (TTM)$-0.31

EBITD / Share (Annual)$-0.39

Operating Margin (Annual)-48325.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-100.13%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.24

P/TBV (Quarterly)6.12x

P/B Ratio (Annual)7.33x

Book Value / Share (Annual)$0.13

Price vs S&P 500 (13W)-2.69%

Beta2.67x

Revenue / Share (TTM)$0.00

ROE (TTM)-180.13%

52-Week Low$0.87

mGradeB

vgmGradeB

CRDL Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.07	-$0.04	+48.28%(+$0.04)
Q1 2026	May 11, 2026	-$0.06	-$0.07	-11.11%(-$0.01)
Q4 2025	Mar 31, 2026	-$0.08	-$0.05	+36.36%(+$0.03)
Q3 2025	Nov 13, 2025	-$0.07	-$0.08	-14.29%(-$0.01)
Q2 2025	Aug 14, 2025	-$0.09	-$0.07	+20.00%(+$0.01)

CRDL Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.13

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CRDLCardiol Therapeutics Inc. Class A Common Shares	—	—	B	—	—	—	—	$1.10
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Cardiol Therapeutics Inc. Class A Common Shares

Cardiol Therapeutics is a late-stage biopharmaceutical company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead candidate, CardiolRx, is advancing through Phase III trials for pericarditis treatment and has completed Phase II studies in myocarditis and heart failure. The company is also developing CRD-38, a subcutaneous formulation targeting inflammatory heart conditions.

CRDL Next Earnings Report

Report dateNov 12, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.05

Revenue estimate$0

Also reporting on Nov 12, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

NNNNAnbio Biotechnology Class A Ordinary SharesIn Vitro Diagnostics
MSLESatellos Bioscience Inc. Common StockPharmaceuticals
LODEComstock Inc.Industrial Chemicals
CDXSCodexis, Inc.Industrial Chemicals
TLSATiziana Life Sciences Ltd. Common SharesPharmaceuticals
RNAAtrium Therapeutics, Inc. Common StockPharmaceuticals
OGIOrganigram Global Inc. Common SharesPharmaceuticals
NKTXNkarta, Inc. Common StockPharmaceuticals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$0.87

High$2.29